{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:27:12Z","timestamp":1780090032268,"version":"3.54.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research Funds to Promote Hospital Functions Provided by the Japan Organization of Occupational Health and Safety."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12328-023-01756-3","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T17:03:54Z","timestamp":1673283834000},"page":"229-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab\u2013bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen"],"prefix":"10.1007","volume":"16","author":[{"given":"Yorihito","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-1821","authenticated-orcid":false,"given":"Rena","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Uekusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayako","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenari","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"1756_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1756_CR2","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"1756_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1756_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"1756_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"1756_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jso.20301","volume":"91","author":"FA Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91:173\u201380.","journal-title":"J Surg Oncol"},{"key":"1756_CR7","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.2169\/internalmedicine.9393-22","volume":"61","author":"H Hayashi","year":"2022","unstructured":"Hayashi H, Sawada K, Hasebe T, et al. A successful case of hepatocellular carcinoma treated with atezolizumab plus bevacizumab with multisystem immune-related adverse events. Intern Med. 2022;61:3497\u2013502.","journal-title":"Intern Med"},{"key":"1756_CR8","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.6004\/jnccn.2020.7567","volume":"18","author":"G Kichenadasse","year":"2020","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, et al. Multiorgan immune-related adverse events during treatment with atezolizumab. J Natl Compr Canc Netw. 2020;18:1191\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"1756_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295\u2013306.","journal-title":"J Thromb Haemost"},{"key":"1756_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309\u201311.","journal-title":"Arthritis Rheum"},{"key":"1756_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2230.2011.04060.x","volume":"36","author":"L Zhang","year":"2011","unstructured":"Zhang L, Zhou Q, Ma L, et al. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36:344\u201350.","journal-title":"Clin Exp Dermatol"},{"key":"1756_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","volume":"13","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13:1001\u201311.","journal-title":"Oncologist"},{"key":"1756_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","volume":"16","author":"P Gomez","year":"2011","unstructured":"Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist. 2011;16:1508\u201319.","journal-title":"Oncologist"},{"key":"1756_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00066-016-0950-7","volume":"192","author":"S Stieb","year":"2016","unstructured":"Stieb S, Riesterer O, Br\u00fcssow C, et al. Radiation recall dermatitis induced by sorafenib\u202f: a case study and review of the literature. Strahlenther Onkol. 2016;192:342\u20138.","journal-title":"Strahlenther Onkol"},{"key":"1756_CR15","first-page":"2171062","volume":"2018","author":"K Mehta","year":"2018","unstructured":"Mehta K, Kaubisch A, Tang J, et al. Radiation recall dermatitis in patients treated with sorafenib. Case Rep Oncol Med. 2018;2018:2171062.","journal-title":"Case Rep Oncol Med"},{"key":"1756_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3857\/roj.2013.31.3.171","volume":"31","author":"D Oh","year":"2013","unstructured":"Oh D, Park HC, Lim HY, et al. Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction. Radiat Oncol J. 2013;31:171\u20134.","journal-title":"Radiat Oncol J"},{"key":"1756_CR17","first-page":"71","volume":"1","author":"J Robbins","year":"2011","unstructured":"Robbins J, Wollner I, Ryu S. Sorafenib induced radiation recall dermatitis after spine radiosurgery. J Radiosurg SBRT. 2011;1:71\u20134.","journal-title":"J Radiosurg SBRT"},{"key":"1756_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4103\/ijdvl.IJDVL_67_19","volume":"85","author":"CS Sirka","year":"2019","unstructured":"Sirka CS, Sahu K, Pradhan S, et al. Sorafenib-induced grade III hand-foot skin reaction with ulcerative dermatitis on scrotum, penis, and earlobe. Indian J Dermatol Venereol Leprol. 2019;85:623\u20136.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1756_CR19","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.2147\/DDDT.S248850","volume":"14","author":"KC Liu","year":"2020","unstructured":"Liu KC, Hao YH, Lv WF, et al. Transarterial chemoembolization combined with sorafenib in patients with BCLC stage C hepatocellular carcinoma. Drug Des Devel Ther. 2020;14:3461\u20138.","journal-title":"Drug Des Devel Ther"},{"key":"1756_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.aohep.2019.03.008","volume":"18","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, \u00c1lvares-Da-Silva MR. Anaphylaxis preceded by erythema multiforme with sorafenib: first case report. Ann Hepatol. 2019;18:777\u20139.","journal-title":"Ann Hepatol"},{"key":"1756_CR21","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.cgh.2019.05.005","volume":"18","author":"K Dohmen","year":"2020","unstructured":"Dohmen K. Severe ulcerative skin lesions due to lenvatinib. Clin Gastroenterol Hepatol. 2020;18:e113.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1756_CR22","unstructured":"Chugai Pharmaceutical Co., Avastin\u00ae. Summary of Product Characteristics, 2020. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00052871. Accessed 1 Oct 2022."},{"key":"1756_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/cncr.25573","volume":"117","author":"JP Erinjeri","year":"2011","unstructured":"Erinjeri JP, Fong AJ, Kemeny NE, et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117:1296\u2013301.","journal-title":"Cancer"},{"key":"1756_CR24","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.CC.15.00281","volume":"6","author":"Y Suehara","year":"2016","unstructured":"Suehara Y, Osawa H, Kubota D, et al. Large skin ulcer due to a subcutaneous orthopaedic implant after bevacizumab therapy: a case report. JBJS Case Connect. 2016;6: e70.","journal-title":"JBJS Case Connect"},{"key":"1756_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.25259\/IJDVL_398_20","volume":"87","author":"A Vila-Payeras","year":"2021","unstructured":"Vila-Payeras A, Iglesias-Gonz\u00e1lez M, Terrasa-Sagrist\u00e1 F, et al. Cutaneous ulcer with thrombogenic vasculopathy in a patient receiving bevacizumab. Indian J Dermatol Venereol Leprol. 2021;87:268\u201370.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1756_CR26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iwj.13139","volume":"16","author":"JW Ahn","year":"2019","unstructured":"Ahn JW, Shalabi D, Correa-Selm LM, et al. Impaired wound healing secondary to bevacizumab. Int Wound J. 2019;16:1009\u201312.","journal-title":"Int Wound J"},{"key":"1756_CR27","doi-asserted-by":"publisher","DOI":"10.5070\/D3206022869","author":"M Kiuru","year":"2014","unstructured":"Kiuru M, Schwartz M, Magro C. Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy. Dermatol Online J. 2014. https:\/\/doi.org\/10.5070\/D3206022869.","journal-title":"Dermatol Online J"},{"key":"1756_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/14397595.2018.1500437","volume":"29","author":"M Harigai","year":"2019","unstructured":"Harigai M, Nagasaka K, Amano K, et al. 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol. 2019;29:20\u201330.","journal-title":"Mod Rheumatol"},{"key":"1756_CR29","first-page":"989","volume":"81","author":"L Collins","year":"2010","unstructured":"Collins L, Seraj S. Diagnosis and treatment of venous ulcers. Am Fam Physician. 2010;81:989\u201396.","journal-title":"Am Fam Physician"},{"key":"1756_CR30","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.3390\/ijms23126526","volume":"23","author":"EA Burian","year":"2022","unstructured":"Burian EA, Sabah L, Karlsmark T, et al. Cytokines and venous leg ulcer healing-a systematic review. Int J Mol Sci. 2022;23:6526.","journal-title":"Int J Mol Sci"},{"key":"1756_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.clindermatol.2006.09.004","volume":"25","author":"CN Etufugh","year":"2007","unstructured":"Etufugh CN, Phillips TJ. Venous ulcers. Clin Dermatol. 2007;25:121\u201330.","journal-title":"Clin Dermatol"},{"issue":"Suppl 1","key":"1756_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000481241","volume":"93","author":"C Ogawa","year":"2017","unstructured":"Ogawa C, Morita M, Omura A, et al. Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. Oncology. 2017;93(Suppl 1):113\u20139.","journal-title":"Oncology"},{"key":"1756_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474124.2017.1373018","volume":"12","author":"P Wang","year":"2018","unstructured":"Wang P, Tan G, Zhu M, et al. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12:1\u20138.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1756_CR34","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/apt.13977","volume":"45","author":"J Howell","year":"2017","unstructured":"Howell J, Pinato DJ, Ramaswami R, et al. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment Pharmacol Ther. 2017;45:1146\u201355.","journal-title":"Aliment Pharmacol Ther"},{"key":"1756_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71:787\u201394.","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-023-01756-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T08:51:19Z","timestamp":1701679879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-023-01756-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1756"],"URL":"https:\/\/doi.org\/10.1007\/s12328-023-01756-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"8 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedure followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"This study does not contain identifying information of the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}